Advanced Renal Cell Carcinoma: Applying Sequencing Principles in Clinical Practice

Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he applies current guideline recommendations alongside individualized clinical decision making in routine practice. He explains that prior treatment exposure, treatment-related toxicities, and patient fitness are central considerations when selecting subsequent therapy after progression. Dr. Pal outlines his general approach for patients who have or have not previously received cabozantinib, highlighting how tolerability and prior experience with tyrosine kinase inhibitors influence the selection of later-line treatment options. He emphasizes that while several effective therapies are available, choosing the most appropriate first-line regimen remains critical because many patients may not receive multiple subsequent lines of therapy. Dr. Pal concludes by reinforcing the importance of maximizing clinical benefit early in the disease course and tailoring sequencing strategies to each patient's evolving clinical status, treatment history, and overall therapeutic goals in advanced renal cell carcinoma.